PruDensNet: a parameter efficient depthwise separable CNN for MRI-based brain tumor classification - Report - MDSpire

PruDensNet: a parameter efficient depthwise separable CNN for MRI-based brain tumor classification

  • By

  • Mithila Arman

  • Ahnaf Samin

  • A. K. M. Muzahidul Islam

  • Md Maruf Rusafi Arnob

  • Md Jahirul Islam

  • Ishtiak Al Mamoon

  • May 20, 2026

  • 0 min

Share

Clinical Report: PruDensNet: An Efficient Depthwise Separable CNN for Classifying Brain Tumors Using MRI Data

Overview

PruDensNet is a novel depthwise-separable convolutional network designed for efficient brain tumor classification using MRI data, achieving a test accuracy of 96.05%. The architecture emphasizes parameter efficiency and integrates advanced training techniques, making it suitable for cost-sensitive clinical environments.

Background

Automated brain tumor classification using MRI is crucial for effective diagnosis and treatment planning. However, existing methods often struggle with computational costs and variability in imaging protocols. PruDensNet addresses these challenges by providing a lightweight and efficient solution that can be deployed in resource-constrained settings, enhancing clinical workflows.

Data Highlights

MetricValue
Test Accuracy96.05%
Validation Accuracy97.27%
Parameters1.46 M

Key Findings

  • PruDensNet achieves a test accuracy of 96.05% on a four-class brain tumor MRI benchmark.
  • The model utilizes approximately 1.46 million parameters, making it parameter-efficient.
  • It incorporates lightweight channel and spatial attention mechanisms to enhance classification performance.
  • Training methodologies include MixUp, CutMix, and label smoothing, improving robustness without increasing inference costs.
  • The architecture is designed for deployment in latency-sensitive clinical environments, such as CPU-only workstations.

Clinical Implications

The development of PruDensNet offers a promising tool for clinicians in need of efficient and accurate brain tumor classification from MRI scans. Its lightweight design allows for integration into existing clinical workflows without significant resource demands, potentially improving patient outcomes through timely diagnosis.

Conclusion

PruDensNet represents a significant advancement in the field of MRI-based brain tumor classification, balancing accuracy and efficiency. Further validation in diverse clinical settings will be essential to confirm its utility in practice.

Related Resources & Content

  1. European Radiology, 2023 -- Rapid and Reliable Brain Extraction from Contrast-Enhanced T1-Weighted MRI in Tumor Presence: An Enhanced Model Utilizing Multi-Center Data
  2. npj Digital Medicine, 2023 -- DARE-FUSE: A Unified Framework for Evidence-Based Learning in MRI Segmentation and Classification of Brain Tumors
  3. DeepSeg, 2020 -- A Deep Learning Framework for Automated Segmentation of Brain Tumors in Magnetic Resonance FLAIR Imaging
  4. Frontiers in Medicine, 2026 -- CMRA-DETR: A Lightweight and High-Accuracy Detection Framework for MRI-Based Brain Tumor Identification
  5. ACR Appropriateness Criteria® Brain Tumors - PubMed
  6. ASTRO updates guideline on radiation therapy for high-grade diffuse glioma - American Society for Radiation Oncology (ASTRO)
  7. Diagnostic performance of deep learning for predicting glioma isocitrate dehydrogenase and 1p/19q co-deletion in MRI: a systematic review and meta-analysis | European Radiology | Springer Nature Link
  8. ACR Appropriateness Criteria® Brain Tumors - PubMed
  9. ASTRO updates guideline on radiation therapy for high-grade diffuse glioma - American Society for Radiation Oncology (ASTRO)
  10. Diagnostic performance of deep learning for predicting glioma isocitrate dehydrogenase and 1p/19q co-deletion in MRI: a systematic review and meta-analysis | European Radiology | Springer Nature Link

Original Source(s)

Related Content